BioMarin Pharmaceutical Inc.
BMRN
$68.32
$0.380.56%
| Weiss Ratings | BMRN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | C | |||
| Rating Factors | BMRN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Excellent | |||
| Efficiency Index | Good | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BMRN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.12 | |||
| Price History | BMRN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -5.10% | |||
| 30-Day Total Return | 4.13% | |||
| 60-Day Total Return | 2.23% | |||
| 90-Day Total Return | 10.25% | |||
| Year to Date Total Return | 2.75% | |||
| 1-Year Total Return | -21.29% | |||
| 2-Year Total Return | -29.28% | |||
| 3-Year Total Return | -14.90% | |||
| 5-Year Total Return | -20.61% | |||
| 52-Week High % Change | -28.37% | |||
| 52-Week Low % Change | 12.06% | |||
| Price | BMRN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $94.85 | |||
| 52-Week Low Price | $60.63 | |||
| 52-Week Low Price (Date) | Jan 16, 2025 | |||
| 52-Week High Price (Date) | Aug 20, 2024 | |||
| Valuation | BMRN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 12.96B | |||
| Enterprise Value | 12.46B | |||
| Price/Earnings (TTM) | 30.89 | |||
| Earnings Per Share (TTM) | 2.20 | |||
| Earnings Per Share Growth | 157.15% | |||
| Price/Earnings To Growth | 0.20 | |||
| Price/Sales (TTM) | 4.68 | |||
| Price/Book (Q) | 2.29 | |||
| Enterprise Value/Revenue (TTM) | 4.37 | |||
| Price | $68.32 | |||
| Enterprise Value/EBITDA (TTM) | 18.69 | |||
| Enterprise Value/EBIT | 21.85 | |||
| Market Cap Category | Large Cap | |||
| Dividends and Shares | BMRN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 196.58M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BMRN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 415 506 6700 | |||
| Address | 770 Lindaro Street San Rafael, CA 94901 | |||
| Website | www.biomarin.com | |||
| Country | United States | |||
| Year Founded | 1996 | |||
| Profitability | BMRN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 19.97% | |||
| Profit Margin | 14.95% | |||
| Management Effectiveness | BMRN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 5.15% | |||
| Return on Equity | 8.05% | |||
| Income Statement | BMRN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 2.85B | |||
| Total Revenue (TTM) | 2.85B | |||
| Revenue Per Share | $14.52 | |||
| Gross Profit (TTM) | 1.88B | |||
| EBITDA (TTM) | 666.47M | |||
| EBIT (TTM) | 570.04M | |||
| Net Income (TTM) | 426.86M | |||
| Net Income Avl. to Common (TTM) | 426.86M | |||
| Total Revenue Growth (Q YOY) | 15.65% | |||
| Earnings Growth (Q YOY) | 513.22% | |||
| EPS Diluted (TTM) | 2.20 | |||
| EPS Diluted Growth (Q YOY) | 644.69% | |||
| Balance Sheet | BMRN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 1.14B | |||
| Cash Per Share (Q) | $5.79 | |||
| Total Current Assets (Q) | 3.23B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 5.66B | |||
| Current Ratio (Q) | 5.325 | |||
| Book Value Per Share (Q) | $29.66 | |||
| Total Assets (Q) | 6.99B | |||
| Total Current Liabilities (Q) | 606.99M | |||
| Total Debt (Q) | 633.97M | |||
| Total Liabilities (Q) | 1.33B | |||
| Total Common Equity (Q) | 5.66B | |||
| Cash Flow | BMRN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 136.49M | |||
| Cash from Financing (TTM) | -526.45M | |||
| Net Change in Cash (TTM) | 187.72M | |||
| Levered Free Cash Flow (TTM) | 271.54M | |||
| Cash from Operations (TTM) | 572.84M | |||
